Thomas, Merlin

Prof Merlin Thomas

Physician and Research Scientist; Professor of Medicine, Monash University, Melbourne
Dr Merlin Thomas MBChB, PhD, FRACP is a Professor of Medicine at Monash University, Melbourne. Professor Thomas is both a physician and a research scientist. He has published over 300 articles in many of the world’s leading medical journals, as well as several books including The Longevity List and Fast Living, Slow Ageing. He is internationally recognized as a speaker, opinion-leader, teacher and medical storyteller. His research focuses on discovering new ways to prevent and treat the complications of diabetes.

More from this expert

Podcasts iconPodcasts

CKD is a marker of poor prognosis and if present, we must work hard to prevent adverse outcomes… now is the time for SGLT2i, statins, ace inhibitors, and arbs

Podcasts iconPodcasts

The aim of the game in managing patients with T2DM is to keep them out of hospital; diabetic foot complications are a common and recurrent reason for patients to be admitted to hospitals

This article discusses common co-morbidities of type 2 diabetes and poor kidney function, and how optimal management must account for the mutual effects of one condition on the other.

Monographs iconMonographs

This article discusses how to assess abnormal liver function in a patient with type 2 diabetes, and the importance of managing this condition to improve long-term health outcomes.

Monographs iconMonographs

This article discusses the complications and considerations associated with managing older patients with type 2 diabetes and the need for an individualised approach.

Monographs iconMonographs

This article discusses the evidence for using a combination of SGLT2 inhibitors & DPP-4 inhibitors in addition to standard care for the management of type 2 diabetes and its complications.

Monographs iconMonographs

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

Monographs iconMonographs

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

Monographs iconMonographs

This article discusses the evidence for the combination use of SGLT2 inhibitors and DPP4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

Monographs iconMonographs

CKD is a marker of poor prognosis and if present, we must work hard to prevent adverse outcomes… now is the time for SGLT2i, statins, ace inhibitors, and arbs

Podcasts iconPodcasts

The aim of the game in managing patients with T2DM is to keep them out of hospital; diabetic foot complications are a common and recurrent reason for patients to be admitted to hospitals

Podcasts iconPodcasts